Helocyte, Inc., a subsidiary of Fortress Biotech, Inc., specializes in the development and commercialization of novel immunotherapies aimed at preventing and treating cancer and infectious diseases, with a particular focus on cytomegalovirus (CMV). The company operates in the biotechnology sector, targeting healthcare providers and patients who require advanced therapeutic solutions for CMV and other related conditions. Helocyte's business model revolves around the research, development, and eventual commercialization of its proprietary immunotherapy products. Revenue is generated through product sales, licensing agreements, and strategic partnerships. The company's flagship product, the Triplex vaccine, has shown promising results in Phase 1 clinical trials, demonstrating favorable safety and immunogenicity at multiple dose levels in healthy volunteers. Helocyte is committed to strategic growth through targeted product acquisition and actively seeks in-licensing, co-development, and other partnering opportunities that align with its expertise and enhance its pipeline.

Keywords: immunotherapy, cytomegalovirus, cancer treatment, infectious diseases, biotechnology, Triplex vaccine, clinical trials, strategic partnerships, product acquisition, healthcare.